Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk

doi:10.1016/j.annonc.2020.08.1408

HFCAS OpenIR

	Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk
	Gao, M.1,2,3; Chi, Y.4; Tang, P.5; Zheng, X.1,2,3; Xu, Z.6; Li, D.1,2,3 ; Chen, X.7; Ge, M.8,9,10,11,12; Zhang, Y.13; Guo, Z.14; Wang, J.15; Chen, J.16; Zhang, J.17; Cheng, Y.18; Li, Z.19; Liu, H.20; Qin, J.21,22; Zhu, J.23; Cheng, R.24
	2020-09-01
发表期刊	ANNALS OF ONCOLOGY
ISSN	0923-7534
DOI	10.1016/j.annonc.2020.08.1408
收录类别	SCI
语种	英语
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000573469102504
出版者	ELSEVIER
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/104426
专题	中国科学院合肥物质科学研究院
作者单位	1.Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China 2.Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China 3.Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China 4.Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 5.Chinese Acad Med Sci & Peking Union Med Coll, Dept VIP, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 6.Chinese Acad Med Sci & Peking Union Med Coll, Head & Neck Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China 7.Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China 8.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Head & Neck Surg, Hangzhou, Peoples R China 9.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 10.Zhejiang Canc Hosp, Hangzhou, Peoples R China 11.Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China 12.Hangzhou Med Coll, Peoples Hosp, Hangzhou, Peoples R China 13.Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Head & Neck Surg Dept,Jiangsu Canc Hosp, Nanjing, Peoples R China 14.Sun Yat Sen Univ, Ctr Canc, Head & Neck Surg, Guangzhou, Peoples R China 15.Gansu Prov Canc Hosp, Head & Neck Surg, Lanzhou, Peoples R China 16.Hunan Canc Hosp, Head & Neck Surg Dept 1, Changsha, Peoples R China 17.Harbin Med Univ, Canc Hosp, Thyroid Surg Ward, Harbin, Peoples R China 18.Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China 19.China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Dept Head & Neck Surg, Shenyang, Peoples R China 20.Fujian Canc Hosp, Head & Neck Dept, Fuzhou, Peoples R China 21.Zhengzhou Univ, Affiliated Canc Hosp, Thyroid & Head & Neck Surg, Zhengzhou, Peoples R China 22.Henan Canc Hosp, Zhengzhou, Peoples R China 23.Sichuan Univ, West China Hosp, Thyroid Surg, Chengdu, Peoples R China 24.Kunming Med Univ, Affiliated Hosp 1, Dept Thyroid Surg, Kunming, Yunnan, Peoples R China
推荐引用方式 GB/T 7714	Gao, M.,Chi, Y.,Tang, P.,et al. Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk[J]. ANNALS OF ONCOLOGY,2020,31.
APA	Gao, M..,Chi, Y..,Tang, P..,Zheng, X..,Xu, Z..,...&Cheng, R..(2020).Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk.ANNALS OF ONCOLOGY,31.
MLA	Gao, M.,et al."Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk".ANNALS OF ONCOLOGY 31(2020).